Also known as GlucaGen · Baqsimi · Gvoke
Insulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
Glucagon is the metabolic mirror image of insulin. Released by the pancreatic alpha cells when blood sugar falls, this 29-amino-acid peptide tells the liver to break down glycogen and make new glucose, pushing blood sugar back up. It is the body’s primary defense against hypoglycemia, the basis of emergency rescue products, and — in a development that has put it back at the center of metabolic drug design — one of the three receptors the newest weight-loss agonists deliberately engage.
Glucagon and insulin are a push-pull pair: insulin lowers blood glucose, glucagon raises it, and health depends on their balance. When blood sugar drops dangerously — most often in insulin-treated diabetes — glucagon is the rescue, which is why it is sold as emergency kits: the classic reconstituted injection (GlucaGen), a nasal powder (Baqsimi, 2019), and a ready-to-use autoinjector (Gvoke). It is also used in radiology and endoscopy to relax smooth muscle.
As a molecule it is a 29-residue peptide derived from the same precursor (preproglucagon) that gives rise to GLP-1 and GLP-2 — a family relationship that matters more than it first appears. For decades glucagon was framed only as the hormone you suppress in diabetes. The reframing came from drug design: adding glucagon-receptor agonism to incretin drugs increases energy expenditure and fat mobilization, and the glucagon receptor is the "G" in the GIP/GLP-1/glucagon triple agonists (such as retatrutide) now posting the largest weight-loss numbers in trials.
That is the forward-looking turn — the same hormone that, unopposed, worsens diabetic hyperglycemia becomes, when balanced against incretin signaling, a lever for greater fat loss and metabolic rate. It is a clean example of how a "bad" hormone in one context is a deliberate design ingredient in another.
Binds the glucagon receptor on hepatocytes, raising cAMP and driving glycogenolysis and gluconeogenesis to increase blood glucose. It opposes insulin in the moment-to-moment regulation of blood sugar.
Behind every vial of Glucagon is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Glucagon, specifically, is brought into being.
On paper, Glucagon is C153H225N43O49S — about 3,485 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Glucagon means roughly 29 coupling cycles on the synthesizer — one protected residue added at a time, which is also 29 chances for an incomplete coupling to seed a deletion impurity.
The crude mixture — Glucagon plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of Glucagon proves itself: identity confirmed by mass spectrometry against its ~3,485 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Glucagon — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Glucagon is a 29-residue peptide produced by chemical synthesis or recombinant expression. It is prone to aggregation and fibrillation in aqueous solution, which is why traditional products are lyophilized and reconstituted at the point of use, and why newer formulations engineered for ready-to-use stability were a meaningful advance.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Glucagon, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Glucagon raises blood sugar — it is the counter-hormone to insulin. The pancreas releases it when glucose falls, signaling the liver to release stored glucose. As a drug it is the emergency rescue for severe hypoglycemia.
Glucagon-receptor agonism increases energy expenditure and fat mobilization. It is the "G" in the GIP/GLP-1/glucagon triple agonists (like retatrutide) that show the largest weight-loss effects in trials.
Both come from the same precursor protein, preproglucagon. Glucagon raises blood sugar; GLP-1 lowers it and curbs appetite — different products of one parent molecule.
No — this is a research and educational reference, not dosing guidance.